Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Faculty Opinions recommendation of Guidelines for the use of flow cytometry and cell sorting in immunological studies.
Lehrke, Michael Jonathan , Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.731982221.793557362 Get It

Expertise in Head and Neck Cutaneous Reconstructive Surgery
Deng, Min , Higgins, H. William , Lesiak, Kendra, Decker, Ashley B., Regula, Christie G., Stevenson, Mary L. , Raphael, Brian A., DePry, Jennifer L., Scott, Jeffrey F. , Bangash, H. , Ochoa, Shari A. , Ibrahimi, Omar A. , Shafai, Aria, Bordeaux, Jeremy S. , Carucci, John A. , Cook, Jonathan L. , Goldman, Glenn D., Rohrer, Thomas E. , Lawrence, Naomi, Deng, Min, Decker, Ashley

Mayo Clinic

Dermatologic Surgery | March 13, 2019 | Volume: 45 | Issue: 6 | Pages: 782-790

10.1097/dss.0000000000001844 | PMID 30829776 Get It

BACKGROUND The management of skin cancers has evolved with the development of Mohs micrographic surgery and a greater emphasis on surgical training within dermatology. It is unclear whether these changes have translated into innovations and contributions to the reconstructive literature. OBJECTIVE To assess contributions from each medical specialty to the cutaneous head and neck oncologic reconstructive literature. METHODS The authors conducted a systematic review of the head and neck reconstructive literature from 2000 through 2015 based on a priori search terms relating to suture technique, linear closure, advancement, rotation, transposition and interpolation flaps, and identified the specialty of the senior authors. RESULTS The authors identified 74,871 articles, of which 1,319 were relevant. Under suture technique articles, the senior authors were primarily dermatologists (58.2%) and plastic surgeons (20.3%). Under linear closure, the authors were dermatologists (48.1%), plastic surgeons (22.2%), and otolaryngologists (20.4%). Under advancement and rotation flaps, the senior authors were plastic surgeons (40.5%, 38.9%), dermatologists (38.1%, 34.2%), and otolaryngologists (14.4%, 21.6%). Under transposition and interpolation flaps, the senior authors were plastic surgeons (47.3%, 39.4%), dermatologists (32.3%, 27.0%), and otolaryngologists (15.3%, 23.4%). CONCLUSION The primary specialties contributing to the cutaneous head and neck reconstructive literature are plastic surgery, dermatology, and otolaryngology.
Factors Affecting Return to Play After Primary Achilles Tendon Tear: A Cohort of NFL Players
Yang, Jae-Won, Hodax, Jonathan D., Krill, Michael K. , Lemme, Nicholas J. , Durand, Wesley M. , Hoffman, Joshua, Hewett, Timothy E. , Machan, Jason T. , Owens, Brett D.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 12, 2019 | Volume: 7 | Issue: 3 | Pages: No page available

10.1177/2325967119830139 | PMID 30886876 Get It

Background: Achilles tendon tears are potentially career-ending injuries for professional athletes. For players in the National Football League (NFL), return requires not only surgery and extensive rehabilitation but also the ability to compete in a market with limited positions that annually introduces new recruits. Purpose/Hypothesis: We authors sought to evaluate factors related to return to play (RTP) and changes in performance following a primary Achilles tear. Our hypothesis was that “skilled” position players and those drafted in later rounds would return at a lower rate as compared with “unskilled” position players and higher draft-round players. Study Design: Case-control study; Level of evidence, 3. Methods: From a previously established database, 80 NFL players were identified as having primary Achilles tendon tears between the 2009 and 2014 seasons. RTP was defined as playing in a regular season or postseason game following injury. Probability of RTP was modeled as a function of time after injury in Kaplan-Meier analysis with demographic variables assessed via generalized linear models. Twelve players (15%) experienced a subsequent Achilles tendon tear during or after the study period and were included in the overall RTP rate but were excluded from performance analyses owing to the confounding effects of an ipsilateral retear or contralateral tear. Results: The overall RTP rate was 61.3%. Age, number of prior seasons, position type, or draft round status did not significantly affect RTP when evaluated with Kaplan-Meier analysis. In the season before their injury, players who did RTP played in a significantly greater number of regular season games (13.7) compared with players who did not RTP (8.71) ( P = .011). Players who did not RTP exhibited a significant decrease in performance in the season preceding injury (12.7 regular season games played 2 seasons preinjury vs 8.71 regular season games played 1 season prior preinjury;, P = .019). Players who returned did not display a significant change in the number of games played or started in seasons following injury when >1 season after return was evaluated. Conclusion: Rate of RTP following primary Achilles tendon tears may be lower than previously published. However, for those able to return, performance only in the season immediately following injury appears to be affected; players return to preinjury levels if given the opportunity to play >1 season after injury.
Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases
Zhao, Lili , Leja, Monika, McHugh, Jonathan B. , Shango, Maryann, Baker, Laurence H. , Schuetze, Scott M. , Chugh, Rashmi , Chugh, Rashmi , Zhao, Lili , Siontis, Brittany L.

Mayo Clinic

Sarcoma | March 10, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-6

10.1155/2019/1960593 | PMID 30962762 Get It

Introduction . Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging resection, incidence of metastases, and limited efficacy of systemic therapies. Methods . A medical record search engine was queried to identify patients diagnosed with PCS from 1992 to 2017 at the University of Michigan. Results . Thirty-nine patients with PCS had a median age of 41 years (range 2–77). Common histologies were angiosarcoma (AS, 14), high-grade undifferentiated pleomorphic sarcoma (UPS, 10), and leiomyosarcoma (LMS, 5). Sites of origin were left atrium (18), right atrium (16), and pericardium (5). AS was the most common right-sided tumor; UPS was more common on the left. Eighteen patients presented with metastases involving lung (10), bone (7), liver (5), and brain (4). Twenty-five patients underwent resection, achieving 3 R 0 resections. Patients received a median of 2 (1–6) systemic therapies. Median overall survival (OS) was 12.1 months (range 0–79). Median OS was 14.0 months and 8.2 months in patients who did or did not undergo resection, respectively ( p = 0.018 ). Brain metastases occurred in 12 (31%) patients, 9 (75%) of whom had left heart tumors, at a median of 8.5 months (range 0–75) from diagnosis. Median OS was 5.6 months (range 0–30) after the diagnosis of brain metastases. Conclusions . PCS portends a poor prognosis, because of difficulty in obtaining complete resection of sarcoma, advanced stage at diagnosis, and high risk of brain metastases. Providers should be aware of the increased risk of brain metastases and consider brain imaging at diagnosis and follow-up.
The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease
Whitwell, Jennifer L. , Martin, Peter R. , Graff‐Radford, Jonathan, Senjem, Matthew L. , Weigand, Stephen D. , Spychalla, Anthony J., Drubach, Daniel A., Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Jack, Clifford R , Senjem, Matthew L , Graff‐Radford, Jonathan , Machulda, Mary M. , Schwarz, Christopher G.

Mayo Clinic

Alzheimer's & Dementia | March 7, 2019 | Volume: 15 | Issue: 5 | Pages: 675-685

10.1016/j.jalz.2018.12.016 | PMID 30853465 Get It

AbstractIntroductionLittle is known about the role of age on neurodegeneration and protein deposition in atypical variants of Alzheimer's disease (AD).MethodsRegional tau and β‐amyloid positron emission tomography standard uptake value ratios and gray matter volumes were calculated in a cohort of 42 participants with atypical AD. The relationship between regional metrics and age was modeled using a Bayesian hierarchical linear model.ResultsAge was strongly associated with tau uptake across all cortical regions, particularly parietal, with greater uptake in younger participants. Younger age was associated with smaller parietal and lateral temporal volumes. Regional β‐amyloid differed little by age. Age showed a stronger association with tau than volume and β‐amyloid in all cortical regions. Age was not associated with cognitive performance.DiscussionAge is an important determinant of severity of cortical tau uptake in atypical AD, with young participants more likely to show widespread and severe cortical tau uptake.
Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.
Kim, William Y. , Sonpavde, Guru , Srinivas, Sandy, Mortazavi, Amir , Watt, Colleen, Mallek, Marissa, Graap, Katherine, Díaz, Carlos Guerrero , Odegaard, Meagan, Apolo, Andrea B , Rosenberg, Jonathan E , Chen, Ronald C. , Diaz, Carlos, Ballman, Karla V. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: TPS504-TPS504

10.1200/jco.2019.37.7_suppl.tps504 Get It

TPS504 Background: Patients with high-risk MIBC have a poor prognosis. Radical cystectomy remains the standard treatment. Yet despite substantial improvements in surgical techniques, mortality from metastatic recurrence remains high. A large number of MIBC patients are ineligible for cisplatin-based chemotherapy or have persistent muscle-invasive disease despite neoadjuvant chemotherapy (NAC). Pembrolizumab, a PD-1 inhibitor, has demonstrated significant activity and is FDA-approved for patients with advanced/chemotherapy-refractory metastatic urothelial carcinoma. We hypothesize that pembrolizumab given post-cystectomy will improve overall survival (OS) and disease-free survival (DFS) in patients with high-risk MIBC. Methods: Patients must have histologically confirmed muscle-invasive urothelial carcinoma of the bladder or upper tract, have received NAC and have ≥ pT2 and/or pN+ at surgery or be cisplatin-ineligible and have ≥ pT3 and/or pN+ at surgery or have declined adjuvant cisplatin-based therapy and have ≥ pT3 and/or pN+ at surgery. Surgery could be radical cystectomy, nephrectomy, or ureterectomy. Patients are stratified by pathologic stage, central PD-L1 status, and prior NAC. Patients are randomized to receive pembrolizumab 240 mg every 3 weeks for 1 year, or observation. The dual primary objectives are to determine DFS and OS. Secondary objectives are to determine DFS and OS in PD-L1-positive and -negative patients and assess safety. Correlative objectives are to determine whether 12 immune gene signatures, tumor molecular subtypes, diversity of T-cell receptor (TCR) clonotypes, persistence of TCR clonotypes, tumor and neoantigen burden, HLA subtypes, and plasma HGF and VEGF levels with IL-10 and IL-17 are associated with OS and DFS. Quality of Life Correlative objectives are to compare health-related quality of life as assessed by the EORTC QLQ-C30. Clinical trial information: NCT03244384.
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.
Divi, Vasu , Cooper, Jay S., McHugh, Jonathan B. , Bell, Diana , Suntharalingam, Mohan, Raben, David, Kim, Harold E., Spencer, Sharon A., Laramore, George E. , Trotti, Andy, Foote, Robert L. , Schultz, Christopher J. , Zhang, Qiang , Harris, Jonathan , Harari, Paul M. , Sturgis, Erich M. , Cmelak, Anthony J. , Thorstad, Wade , Le, Quynh‐Thu , Holsinger, F. Christopher

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6011-6011

10.1200/jco.2015.33.15_suppl.6011 Get It

Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET).
Hobday, Timothy J. , Yin, Jun , Pettinger, Adam, Reidy‐Lagunes, Diane , Chen, Helen X., Erlichman, Charles , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4096-4096

10.1200/jco.2015.33.15_suppl.4096 Get It

SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).
Guthrie, Katherine A. , Moran, César A. , Kulke, Matthew H. , Chan, Jennifer A. , LoConte, Noelle K. , Wolin, Edward M. , Mattar, Bassam, McDonough, Shannon, Chen, Helen X., Blanke, Charles D. , Höchster, Howard S. , LoConte, Noelle , Yao, James C. , Strosberg, Jonathan , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2015.33.15_suppl.4004 Get It